August 6, 2021: Early Treatment of COVID-19 with Repurposed Therapies: The TOGETHER Adaptive Platform Trial (Edward Mills, PhD, FRCP)
After many trial therapies showed little effect, Fluvoxamine, an SSRI commonly used for depression, has shown promising results when repurposed to treat COVID-19.
Fluvoxamine(フルボキサミン)がコロナに対して有意な結果フルボキサミンマレイン酸塩錠50mg「サワイ」薬価18.1円副作用の一部
性機能異常(射精遅延、勃起障害)、性欲低下
前スレ

>>続きを読む